Compare Humana Inc (HUM) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs SOLAI Limited — how do they compare? Humana Inc trades at $406.1 (market cap $47.81B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Humana Inc is far larger — about 2864.6× SOLAI Limited's market cap, and Humana Inc pays a 0.89% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| HUM | SLAI | |
|---|---|---|
Market Cap | $47.81B | $16.69M |
Sector | Health | Technology |
52-Week High | $409.42 | $26.74 |
52-Week Low | $163.67 | $2.74 |
Enterprise Value | $56.85B | $16.33M |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
SLAI trades at $3.72 with no recent price movement, while facing NYSE delisting proceedings announced July 16, 2026. The company shows severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include a 7:1 reverse stock split effective June 2026 and acquisition of a 51% stake in NEURALAND. Technical indicators show mixed signals with an overall bullish trend but overbought RSI conditions.
The outlook remains highly speculative given delisting risks and persistent losses. Investment opportunity exists only for speculative traders betting on turnaround potential from recent acquisitions and AI product launches. Primary risks include imminent delisting, negative cash flow, and unsustainable financial performance that threatens ongoing operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
